Trial Profile
A randomized, double-blind, placebo-controlled, multiple dose phase 2 study to determine the safety and efficacy of AMG 317 in subjects with moderate to severe asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2016
Price :
$35
*
At a glance
- Drugs AMG 317 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 07 Jan 2010 Results published in the American Journal of Respiratory and Critical Care Medicine.
- 14 Apr 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
- 14 Apr 2009 Actual patient number (294) added as reported by ClinicalTrials.gov.